Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Galantamine is an alkaloid extracted from snowdrop flowers that reversibly inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. This mechanism increases acetylcholine availability in the brain, making it FDA-approved for mild to moderate Alzheimer's disease treatment.
Origin & History
Galantamine is an Amaryllidaceae-type alkaloid first isolated from the snowdrop Galanthus woronowii, primarily sourced from plants in the Amaryllidaceae family including Leucojum aestivum (bulbs and leaves), Narcissus species, and Lycoris radiata. It is extracted from dried plant material using methods like ethanol percolation or acidic extraction, then purified to >99% purity via HPLC, and typically isolated as galantamine hydrobromide for pharmaceutical use.
Research Narrative (Provisional)
The available research focuses primarily on phytochemical extraction methods rather than clinical outcomes. While galantamine hydrobromide is noted as marketed for Alzheimer's disease and neurological conditions as an acetylcholinesterase inhibitor, the search results lack details on key human clinical trials, RCTs, or meta-analyses, with no PubMed PMIDs provided.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Galantamine is a tertiary isoquinoline alkaloid (molecular formula C₁₇H₂₁NO₃, molecular weight 287.35 g/mol) and is not a nutritional substance; it has no macronutrient, vitamin, mineral, or fiber content. It is a bioactive pharmacological compound naturally occurring in several Amaryllidaceae species. Key biochemical and source concentration data: • Found in Galanthus nivalis (common snowdrop) bulbs at approximately 0.1–0.2% dry weight; Galanthus woronowii at ~0.1–0.3% dry weight; Narcissus pseudonarcissus (daffodil) bulbs at ~0.05–0.1% dry weight; Leucojum aestivum (summer snowflake) at approximately 0.1–0.15% dry weight; Lycoris radiata (red spider lily) at trace to ~0.05% dry weight. • Bioactive compound class: Amaryllidaceae alkaloid, phenanthrene-type (specifically a dibenzofuran alkaloid subclass). • Mechanism of action: Reversible, competitive acetylcholinesterase (AChE) inhibitor (IC₅₀ ~0.35–0.50 µM for human AChE) and allosteric positive modulator of nicotinic acetylcholine receptors (nAChRs), particularly α4β2 and α7 subtypes. • Bioavailability: Oral bioavailability in humans is approximately 80–100% with rapid gastrointestinal absorption; peak plasma concentration (Tmax) reached in approximately 1–2 hours; plasma protein binding ~18%; elimination half-life ~5–7 hours; volume of distribution ~175 L; crosses the blood-brain barrier readily due to lipophilicity (logP ~1.08). Metabolized primarily by hepatic CYP2D6 and CYP3A4 enzymes via O-demethylation and N-demethylation. • Pharmaceutical dosing context: Typical clinical doses range from 4 mg twice daily (initial) to 12 mg twice daily (maintenance) as galantamine hydrobromide in Alzheimer's disease therapy. • No caloric value, no protein, no carbohydrate, no fat, no dietary fiber, no vitamins, and no minerals are contributed by the isolated compound itself. It is classified strictly as a pharmacologically active alkaloid, not a food or supplement nutrient.
Reported Mechanism (Provisional)
Galantamine works through dual mechanisms: reversible inhibition of acetylcholinesterase enzyme and allosteric modulation of nicotinic acetylcholine receptors. By blocking acetylcholinesterase, it prevents the breakdown of acetylcholine in synaptic clefts, while its nicotinic receptor modulation enhances cholinergic neurotransmission. This combined action increases acetylcholine availability and improves cholinergic signaling in brain regions affected by neurodegeneration.
Clinical Narrative (Provisional)
Multiple randomized controlled trials have established galantamine's efficacy for Alzheimer's disease, with studies showing 4-7 point improvements on the ADAS-cog cognitive scale at 16-24mg daily doses over 3-6 months. A meta-analysis of 7 trials involving 6,805 patients demonstrated significant cognitive benefits compared to placebo. Some smaller studies have explored galantamine for mild cognitive impairment and lucid dreaming enhancement, though evidence for these applications remains limited. The pharmaceutical formulation (Razadyne) has over 20 years of clinical use data.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.